An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
Latest Information Update: 16 Mar 2023
At a glance
- Drugs Pamiparib (Primary) ; Tislelizumab (Primary)
- Indications Cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms IMPARP-HRD
- 03 Mar 2022 Status changed from not yet recruiting to recruiting.
- 09 Aug 2021 New trial record